Amicus Therapeutics - Stock Price History | FOLD
Historical daily share price chart and data for Amicus Therapeutics since 2021 adjusted for splits. The latest closing stock price for Amicus Therapeutics as of October 22, 2021 is 10.50.
- The all-time high Amicus Therapeutics stock closing price was 24.89 on December 22, 2020.
- The Amicus Therapeutics 52-week high stock price is 25.39, which is 141.8% above the current share price.
- The Amicus Therapeutics 52-week low stock price is 8.60, which is 18.1% below the current share price.
- The average Amicus Therapeutics stock price for the last 52 weeks is 13.65.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Amicus Therapeutics Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2020 |
14.2237 |
9.5500 |
24.8900 |
6.6300 |
23.0900 |
137.06% |
| 2019 |
11.2103 |
10.0400 |
14.4000 |
7.4800 |
9.7400 |
1.67% |
| 2018 |
13.8221 |
15.1600 |
17.1200 |
8.3800 |
9.5800 |
-33.43% |
| 2017 |
10.3500 |
5.1300 |
16.2400 |
5.1300 |
14.3900 |
189.54% |
| 2016 |
6.9360 |
9.0300 |
9.3500 |
4.5300 |
4.9700 |
-48.76% |
| 2015 |
11.4110 |
8.6100 |
18.2300 |
5.9500 |
9.7000 |
16.59% |
| 2014 |
4.2658 |
2.4100 |
8.6100 |
1.8200 |
8.3200 |
254.04% |
| 2013 |
2.7800 |
2.8400 |
4.2200 |
1.9700 |
2.3500 |
-12.31% |
| 2012 |
5.2648 |
3.5700 |
6.8800 |
2.5300 |
2.6800 |
-22.09% |
| 2011 |
5.3292 |
4.5600 |
7.9400 |
2.1000 |
3.4400 |
-26.81% |
| 2010 |
3.4267 |
3.8400 |
4.8000 |
1.9500 |
4.7000 |
18.39% |
| 2009 |
7.9094 |
8.0000 |
12.2700 |
3.3600 |
3.9700 |
-50.25% |
| 2008 |
11.2884 |
10.3400 |
17.9500 |
7.5000 |
7.9800 |
-25.77% |
| 2007 |
13.8496 |
14.4300 |
18.0400 |
9.5400 |
10.7500 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.804B |
$0.261B |
|
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
|
